ANI Pharmaceuticals Files 8-K on Financials
Ticker: ANIP · Form: 8-K · Filed: Apr 17, 2024 · CIK: 1023024
| Field | Detail |
|---|---|
| Company | Ani Pharmaceuticals Inc (ANIP) |
| Form Type | 8-K |
| Filed Date | Apr 17, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, regulation-fd, exhibits
TL;DR
ANI Pharma dropped an 8-K, check their financials.
AI Summary
On April 17, 2024, ANI Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along with Regulation FD disclosures and financial statements. No specific financial figures or significant events were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates that ANI Pharmaceuticals is providing updates on its financial performance and operational results to the public.
Risk Assessment
Risk Level: low — The filing is a standard disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- ANI PHARMACEUTICALS, INC. (company) — Registrant
- 210 Main Street West (address) — Principal executive offices
- BAUDETTE (city) — Principal executive offices
- MN (state) — Principal executive offices
- 56623 (zip_code) — Principal executive offices
- ( 218 ) 634-3500 (phone_number) — Registrant's telephone number
- BIOSANTE PHARMACEUTICALS INC (company) — Former company name
- BEN ABRAHAM TECHNOLOGIES INC (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing by ANI Pharmaceuticals?
The primary purpose of this 8-K filing is to report on the company's results of operations and financial condition, provide Regulation FD disclosures, and submit financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on April 17, 2024.
What is the principal executive office address for ANI Pharmaceuticals?
The principal executive office address is 210 Main Street West, Baudette, Minnesota 56623.
What were ANI Pharmaceuticals' former company names?
ANI Pharmaceuticals' former company names were BIOSANTE PHARMACEUTICALS INC and BEN ABRAHAM TECHNOLOGIES INC.
What is the SIC code for ANI Pharmaceuticals?
The Standard Industrial Classification (SIC) code for ANI Pharmaceuticals is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 538 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-04-17 07:59:41
Filing Documents
- ani-20240417.htm (8-K) — 29KB
- exhibit991investordeckap.htm (EX-99.1) — 33KB
- exhibit991investordeckap001.jpg (GRAPHIC) — 56KB
- exhibit991investordeckap002.jpg (GRAPHIC) — 318KB
- exhibit991investordeckap003.jpg (GRAPHIC) — 115KB
- exhibit991investordeckap004.jpg (GRAPHIC) — 129KB
- exhibit991investordeckap005.jpg (GRAPHIC) — 101KB
- exhibit991investordeckap006.jpg (GRAPHIC) — 94KB
- exhibit991investordeckap007.jpg (GRAPHIC) — 112KB
- exhibit991investordeckap008.jpg (GRAPHIC) — 97KB
- exhibit991investordeckap009.jpg (GRAPHIC) — 161KB
- exhibit991investordeckap010.jpg (GRAPHIC) — 119KB
- exhibit991investordeckap011.jpg (GRAPHIC) — 107KB
- exhibit991investordeckap012.jpg (GRAPHIC) — 147KB
- exhibit991investordeckap013.jpg (GRAPHIC) — 171KB
- exhibit991investordeckap014.jpg (GRAPHIC) — 148KB
- exhibit991investordeckap015.jpg (GRAPHIC) — 152KB
- exhibit991investordeckap016.jpg (GRAPHIC) — 56KB
- exhibit991investordeckap017.jpg (GRAPHIC) — 108KB
- exhibit991investordeckap018.jpg (GRAPHIC) — 117KB
- 0001023024-24-000050.txt ( ) — 3376KB
- ani-20240417.xsd (EX-101.SCH) — 2KB
- ani-20240417_lab.xml (EX-101.LAB) — 21KB
- ani-20240417_pre.xml (EX-101.PRE) — 12KB
- ani-20240417_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On April 17, 2024, Nikhil Lalwani, President & CEO, and Stephen P. Carey, Chief Financial Officer, both of ANI Pharmaceuticals, Inc. will meet with investors at the Piper Sandler Spring Biopharma Symposium. A copy of the investor presentation is attached as Exhibit 99.1 hereto and incorporated herein by reference.*
01
Item 7.01 Regulation FD Disclosure The information included under Item 2.02 of this Current Report on Form 8-K is incorporated into this Item 7.01 by reference.*
01 Exhibits
Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 99.1 Investor Presentation, dated April 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) * The information in Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 17, 2024 ANI PHARMACEUTICALS, INC. By: /s/ Stephen P. Carey Name: Stephen P. Carey Title: Senior Vice President Finance and Chief Financial Officer